AAAAAA
Results:
1-23
|
Results: 23
Authors:
Wagener, FADTG
Abraham, NG
van Kooyk, Y
de Witte, T
Figdor, CG
Citation: Fadtg. Wagener et al., Heme-induced cell adhesion in the pathogenesis of sickle-cell disease and inflammation, TRENDS PHAR, 22(2), 2001, pp. 52-54
Authors:
Schaap, N
Schattenberg, A
Bar, B
Preijers, F
van Kemenade, EV
de Witte, T
Citation: N. Schaap et al., Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donorleukocyte infusions, LEUKEMIA, 15(9), 2001, pp. 1339-1346
Authors:
Smeets, M
Raymakers, R
Muus, P
Vierwinden, G
Linssen, P
Masereeuw, R
de Witte, T
Citation: M. Smeets et al., Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance, LEUKEMIA, 15(1), 2001, pp. 80-88
Authors:
van Oosterhout, YVJM
van Emst, JL
Bakker, HH
Preijers, FWMB
Schattenberg, AVMB
Ruiter, DJ
Evers, S
Koopman, JP
de Witte, T
Citation: Yvjm. Van Oosterhout et al., Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study, INT J PHARM, 221(1-2), 2001, pp. 175-186
Authors:
Dolstra, H
Fredrix, H
van der Meer, A
de Witte, T
Figdor, C
van de Wiel-van Kemenade, E
Citation: H. Dolstra et al., Immunobiology - TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells, BONE MAR TR, 27(10), 2001, pp. 1087-1093
Authors:
de Witte, T
Suciu, S
Verhoef, G
Labar, B
Archimbaud, E
Aul, C
Selleslag, D
Ferrant, A
Wijermans, P
Mandelli, F
Amadori, S
Jehn, U
Muus, P
Boogaerts, M
Zittoun, R
Gratwohl, A
Zwierzina, H
Hagemeijer, A
Willemze, R
Citation: T. De Witte et al., Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS, BLOOD, 98(8), 2001, pp. 2326-2331
Authors:
Wagener, FADTG
Eggert, A
Boerman, OC
Oyen, WJG
Verhofstad, A
Abraham, NG
Adema, G
van Kooyk, Y
de Witte, T
Figdor, CG
Citation: Fadtg. Wagener et al., Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase, BLOOD, 98(6), 2001, pp. 1802-1811
Authors:
de Witte, T
Suciu, S
Verhoef, G
Labar, B
Archimbaud, E
Aul, C
Selleslag, D
Ferrant, A
Wijermans, P
Mandelli, F
Amadori, S
Jehn, U
Muus, P
Demuynck, H
Dardenne, M
Zittoun, R
Willemze, R
Gratwohl, A
Apperley, J
Citation: T. De Witte et al., Intensive chemotherapy followed by stem cell transplantation for the treatment of myelodysplastic syndromes, HEMAT BLOOD, 40, 2001, pp. 649-654
Authors:
Greenberg, P
Anderson, J
de Witte, T
Estey, E
Fenaux, P
Gupta, P
Hamblin, T
Hellstrom-Lindberg, E
List, A
Mufti, G
Neuwirtova, R
Ohyashiki, K
Oscier, D
Sanz, G
Sanz, M
Willman, C
Citation: P. Greenberg et al., Problematic WHO reclassification of myelodysplastic syndromes, J CL ONCOL, 18(19), 2000, pp. 3447-3449
Authors:
Oosterveld, M
de Witte, T
Citation: M. Oosterveld et T. De Witte, Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia, BLOOD REV, 14(4), 2000, pp. 182-189
Authors:
Schattenberg, A
Schaap, N
Preijers, F
van der Maazen, R
de Witte, T
Citation: A. Schattenberg et al., Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients, BONE MAR TR, 26(1), 2000, pp. 17-22
Authors:
Simonsson, B
Totterman, T
Hokland, P
Lauria, F
Carella, AM
Fernandez, MN
Rozman, C
Ferrant, A
de Witte, T
Zander, AR
Meier, K
Hansson, F
Citation: B. Simonsson et al., Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation, BONE MAR TR, 25(11), 2000, pp. 1121-1127
Authors:
Frassoni, F
Labopin, M
Powles, R
Mary, JY
Arcese, W
Bacigalupo, A
Bunjes, D
Gluckman, E
Ruutu, T
Schaefer, UW
Sierra, J
Vernant, JP
Willemze, R
de Witte, T
Gorin, NC
Citation: F. Frassoni et al., Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia, LANCET, 355(9213), 2000, pp. 1393-1398
Authors:
de Witte, T
Hermans, J
Vossen, J
Bacigalupo, A
Meloni, G
Jacobsen, N
Ruutu, T
Ljungman, P
Gratwohl, A
Runde, V
Niederwieser, D
van Biezen, A
Devergie, A
Cornelissen, J
Jouet, JP
Arnold, R
Apperley, J
Citation: T. De Witte et al., Haematopoietic stem cell transplantation for patients with myelodysplasticsyndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT), BR J HAEM, 110(3), 2000, pp. 620-630
Authors:
Schaap, N
Schattenberg, A
Bar, B
Mensink, E
de Man, A
van Kessel, AG
de Witte, T
Citation: N. Schaap et al., Red blood cell phenotyping is a sensitive technique for monitoring chronicmyeloid leukaemia patients after T-cell-depleted bone marrow transplantation and after donor leucocyte infusion, BR J HAEM, 108(1), 2000, pp. 116-125
Authors:
van Oosterhout, YVJM
van Emst, L
Schattenberg, AVMB
Tax, WJM
Ruiter, DJ
Spits, H
Nagengast, FM
Masereeuw, R
Evers, S
de Witte, T
Preijers, FWMB
Citation: Yvjm. Van Oosterhout et al., A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease, BLOOD, 95(12), 2000, pp. 3693-3701
Authors:
Zittoun, R
de Witte, T
De Cataldo",Delmer,Gandra,Haak,Ho,Jaksic,Jehn,Louwagie,Peetermans,Sonneveld,Stryckmans,Willemze,Zittoun,Zwierzina,Jaksic,Delmer,Suciu,Solbu
Citation: R. Zittoun et al., A randomized phase II trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia, HEM CELL TH, 41(3), 1999, pp. 127-136
Authors:
Keating, S
de Witte, T
Suciu, S
Mandelli, F
Damasio, E
Willemze, R
Morra, E
Amadori, S
Dardenne, M
Vegna, ML
Zittoun, RA
Citation: S. Keating et al., Centre effect on treatment outcome for patients with untreated acute myelogenous leukaemia? An analysis of the AML 8A study of the Leukemia Cooperative Group of the EORTC and GIMEMA, EUR J CANC, 35(10), 1999, pp. 1440-1447
Authors:
van Horssen, PJ
van Oosterhout, YVJM
Evers, S
Backus, HHJ
van Oijen, MGCT
Bongaerts, R
de Witte, T
Preijers, FWMB
Citation: Pj. Van Horssen et al., Influence of cytotoxicity enhancers in combination with human serum on theactivity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells, LEUKEMIA, 13(2), 1999, pp. 241-249
Authors:
Preijers, FWMB
van Hennik, PB
Schattenberg, A
Ruijs, P
Ploemacher, RE
de Witte, T
Citation: Fwmb. Preijers et al., Counterflow centrifugation allows addition of appropriate numbers of T cells to allogeneic marrow and blood stem cell grafts to prevent severe GVHD without substantial loss of mature and immature progenitor cells, BONE MAR TR, 23(10), 1999, pp. 1061-1070
Authors:
Smeets, MEP
Raymakers, RAP
Vierwinden, G
Pennings, AHM
Wessels, H
de Witte, T
Citation: Mep. Smeets et al., Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance, BLOOD, 94(7), 1999, pp. 2414-2423
Authors:
Guardiola, P
Anderson, JE
Bandini, G
Cervantes, F
Runde, V
Arcese, W
Bacigalupo, A
Przepiorka, D
O'Donnell, MR
Polchi, P
Buzyn, A
Sutton, L
Cazals-Hatem, D
Sale, G
de Witte, T
Deeg, HJ
Gluckman, E
Citation: P. Guardiola et al., Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European group for blood and marrow transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study, BLOOD, 93(9), 1999, pp. 2831-2838
Authors:
de Witte, T
de Koning, J
de Vries, J
Citation: T. De Witte et al., European evaluation of intensive anti-leukemic therapy for patients with MDS trial protocol CRIANT, PL 950357, BIOM HLTH R, 24, 1998, pp. 43-81
Risultati:
1-23
|